Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 000020292 approvals45 trials

DONGWHA PHARM.CO.,LTD

Official website

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

As of 2026-10-11, DONGWHA PHARM.CO.,LTD has 5 Korean MFDS device approvals, 287 Korean MFDS drug approvals, 19 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1897 and listed on KOSPI in 1976, Dongwha Pharm is a diversified company centered on pharmaceuticals. Alongside pharmaceuticals, it operates a medical device manufacturing and sales business, a pharmaceutical distribution chain, and a smaller financial business, and holds a 62.07% stake in medical device maker Medicei Co., Ltd. as its intermediate holding company. In its 97th fiscal period, consolidated revenue was KRW 496.4 billion, up 6.78% year over year, while operating profit fell 98.09% year over year to KRW 256 million.

Regulatory approvals

data.go.kr

287 Korean MFDS drug approvals · 1957–2026 / 5 Korean MFDS device approvals · 2018–2021

  • MFDS drugVITAMINEAM Tablets2026-09-22
    Drug · OTC · Notification202602855
  • MFDS drugBu-Chae Pyo Morning Set Solution2026-09-09
    Drug · OTC · Approval202602696
  • MFDS drugWHALCAB Tab. 10mg (vonoprazan)2026-08-12
    Drug · Prescription · Approval202602348
  • MFDS drugWHALCAB Tab. 20mg (vonoprazan)2026-08-12
    Drug · Prescription · Approval202602349
  • MFDS drugFlofena Soft Cap2026-08-10
    Drug · OTC · Notification202602325
  • MFDS drugPanlong Solution2026-08-10
    Drug · OTC · Notification202602326
  • MFDS drugWhituben Kids Cough Syrup2026-07-13
    Drug · OTC · Notification202602015
  • MFDS drugWhituben Kids Cold Syrup2026-06-10
    Drug · OTC · Notification202601644
  • MFDS drugPravafen Cap.2026-05-29
    Drug · Prescription · Approval202601574
  • MFDS drugK21 Tab. 50mg(Tegoprazan)2026-04-30
    Drug · Prescription · Approval202601289
  • MFDS drugK21 Tab. 25mg(Tegoprazan)2026-04-30
    Drug · Prescription · Approval202601291
  • MFDS drugBibicom solution2026-04-15
    Drug · OTC · Notification202601091
Show 68 more
  • MFDS drugVITA-MINI Tablets2025-12-24
    Drug · OTC · Notification202503381
  • MFDS drugRebapin SR Tablet 150mg2025-10-15
    Drug · Prescription · Approval202502662
  • MFDS drugMagnetar SoftCap.2025-10-14
    Drug · OTC · Notification202502651
  • MFDS drugECCLOCK gel, 5% (Sofpironium Bromide)2025-08-29
    Drug · Prescription · Approval202502275
  • MFDS drugLacto Fresh Tab.2025-07-29
    Drug · OTC · Notification202501960
  • MFDS drugWhituben Kidsfen Syrup2025-06-23
    Drug · OTC · Notification202501547
  • MFDS drugAripico Tab. 2mg2025-06-17
    Drug · Prescription · Approval202501473
  • MFDS drugAripico Tab. 1mg2025-06-12
    Drug · Prescription · Approval202501444
  • MFDS drugPancold A Oral Liquid 30mL2025-05-28
    Drug · OTC · Notification202501327
  • MFDS drugEmfldiem Met XR tab. 10/1000mg2025-04-24
    Drug · Prescription · Approval202500992
  • MFDS drugEmfldiem Met XR tab. 25/1000mg2025-04-24
    Drug · Prescription · Approval202500993
  • MFDS drugVI-LA-BAEL essen Tablets2025-03-17
    Drug · OTC · Notification202500584
  • MFDS drugPANCOLD-H Dry Syrup2025-03-17
    Drug · OTC · Notification202500588
  • MFDS drugDongwha Nicergoline Tab. 10mg(Nicergoline)2025-03-05
    Drug · Prescription · Approval202500496
  • MFDS drugPOWERCOL-NoseQ Soft Capsules2025-01-20
    Drug · OTC · Notification202500153
  • MFDS drugAlbothyl Gargle Solution(benzydamine hydrochloride)2025-01-17
    Drug · OTC · Notification202500139
  • MFDS drugDongwha Memantine tablets 20mg(memantine hydrochloride)2025-01-16
    Drug · Prescription · Approval202500125
  • MFDS drugDongwha Hangsim Tab. 240mg2024-11-15
    Drug · OTC · Notification202402697
  • MFDS drugWhituben S Nasal Spray2024-10-31
    Drug · OTC · Notification202402577
  • MFDS drugComakitenQ Nasal Spray2024-08-13
    Drug · OTC · Notification202401972
  • MFDS drugDongwha Quetiapine tablet 12.5mg2024-07-24
    Drug · Prescription · Approval202401795
  • MFDS drugWhituben Nose Syrup2024-05-29
    Drug · OTC · Notification202401331
  • MFDS drugWhituben Cold Syrup2024-05-28
    Drug · OTC · Notification202401314
  • MFDS drugWhituben Cough Syrup2024-05-27
    Drug · OTC · Notification202401290
  • MFDS drugDongwha Albothyl sol.(Policresulen 50% solution)2024-05-20
    Drug · OTC · Notification202401206
  • MFDS drugPANCOLD Care Solutions2024-03-06
    Drug · OTC · Notification202400486
  • MFDS drugLinaDiem Met. XR tab. 5/1000mg2024-02-22
    Drug · Prescription · Approval202400383
  • MFDS drugLinaDiem Met. XR tab. 2.5/1000mg2024-02-22
    Drug · Prescription · Approval202400388
  • MFDS drugDongwha Nicergoline Tab. 30mg(Nicergoline)2024-02-08
    Drug · Prescription · Approval202400304
  • MFDS drugV100QGOLD Tab.Revoked2024-01-08
    Drug · OTC · Notification202400052
  • MFDS drugVI-LA-BAEL-ED Tablets2023-12-19
    Drug · OTC · Notification202303365
  • MFDS drugVI-LA-BAEL-UP Tablets2023-12-06
    Drug · OTC · Notification202303291
  • MFDS drugEmfldiem Met Tab. 12.5/850mg2023-09-05
    Drug · Prescription · Approval202302633
  • MFDS drugEmfldiem Met Tab. 12.5/1000 mg2023-09-05
    Drug · Prescription · Approval202302635
  • MFDS drugEmfldiem Met Tab. 12.5/500 mgRevoked2023-09-05
    Drug · Prescription · Approval202302634
  • MFDS drugFOXIFLE DUO XR TAB. 10/500 mgRevoked2023-06-21
    Drug · Prescription · Approval202301899
  • MFDS drugDryan liquid(aluminum chloride)2023-05-30
    Drug · OTC · Notification202301701
  • MFDS drugDasidiem Tab.10/100 mg (dapagliflozin,sitagliptin)2023-05-16
    Drug · Prescription · Approval202301577
  • MFDS drugWHAL MATE Tablets2023-04-11
    Drug · OTC · Notification202301185
  • MFDS drugDafldiem Met XR Tab. 10/500mg2023-01-31
    Drug · Prescription · Approval202300430
  • MFDS drugDafldiem Met XR Tab. 10/1000mg2023-01-31
    Drug · Prescription · Approval202300431
  • MFDS drugWhituben Q Plus Soft Cap.2023-01-06
    Drug · OTC · Notification202300071
  • MFDS drugWhituben Q Plus nose Soft Cap.2023-01-06
    Drug · OTC · Notification202300078
  • MFDS drugFOXIFLE DUO XR TAB. 10/1000 mgRevoked2023-01-06
    Drug · Prescription · Approval202300148
  • MFDS drugWhituben Q Plus cough Soft Cap.2023-01-02
    Drug · OTC · Notification202300008
  • MFDS drugSitDeim Met tab.50/500mg2022-12-21
    Drug · Prescription · Approval202204588
  • MFDS drugSitDeim Met tab.50/850mg2022-12-21
    Drug · Prescription · Approval202204589
  • MFDS drugSitDeim Met tab.50/1000mg2022-12-21
    Drug · Prescription · Approval202204590
  • MFDS drugBu-Chae Pyo Shib Ccin Tang2022-08-26
    Drug · OTC · Notification202203395
  • MFDS drugSitdiem Met XR Tab. 50/1000 mg2022-05-10
    Drug · Prescription · Approval202201898
  • MFDS drugSitdiem Met XR Tab. 100/1000mg2022-05-10
    Drug · Prescription · Approval202201899
  • MFDS drugSitdiem Met XR Tab. 50/500mg2022-05-10
    Drug · Prescription · Approval202201900
  • MFDS drugEmfldiem Met Tab. 5/850 mgRevoked2022-04-22
    Drug · Prescription · Approval202201662
  • MFDS drugEmfldiem Met Tab. 5/500 mgRevoked2022-04-22
    Drug · Prescription · Approval202201663
  • MFDS drugEmfldiem Met Tab. 5/1000 mgRevoked2022-04-22
    Drug · Prescription · Approval202201664
  • MFDS drugTediem Met XR Tab. 10/500 mg2022-04-04
    Drug · Prescription · Approval202201435
  • MFDS drugTediem Met XR Tab. 20/1000 mg2022-04-04
    Drug · Prescription · Approval202201436
  • MFDS drugTediem Met XR Tab. 10/750 mg2022-04-04
    Drug · Prescription · Approval202201437
  • MFDS drugBargio Once Solution2022-02-09
    Drug · OTC · Notification202200638
  • MFDS drugRABEDUET Tab. 20/500mg2022-01-27
    Drug · Prescription · Approval202200475
  • MFDS drugRABEDUET Tab. 10/500mg(Rabeprazole Sodium, Sodium Bicarbonate)2021-12-31
    Drug · Prescription · Approval202108210
  • MFDS drugWHAL MATE Tablets2021-12-30
    Drug · OTC · Notification202108193
  • MFDSDressing, fluid-impermeable film2021-12-16
    Product approval · Class 2제인 21-5046 호
  • MFDSDressing, fluid-impermeable film2021-12-16
    Product approval · Class 2제인 21-5045 호
  • MFDS drugRivacor tab. 2.5mg(Rivaroxaban)Revoked2021-08-27
    Drug · Prescription · Approval202106198
  • MFDS drugSOGAFTEN Tab.2021-07-07
    Drug · OTC · Notification202105133
  • MFDSDressing, fluid-impermeable film2021-06-16
    Product approval · Class 2제인 21-4525 호
  • MFDS drugTediem tab. 20mg2021-04-20
    Drug · Prescription · Approval202103223

Showing the 80 most recent of 292 records.

Clinical trials

data.go.kr

45 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 20 · Phase 1 19 · Phase 2 2 · Phase 3 2 · Phase 2a 1)

  • Phase 1DW60252026-05-26

    1 trial site

  • BioequivalenceDW6018B 25mg2024-09-23

    1 trial site

  • BioequivalenceDW6018B 25mg2024-09-20

    1 trial site

  • BioequivalenceDW6019정 60 mg2024-05-28

    1 trial site

  • BioequivalenceDW60182024-02-19

    1 trial site

  • BioequivalenceDW60182024-02-06

    1 trial site

  • BioequivalenceDW60172023-07-21

    1 trial site

  • BioequivalenceDW51082023-02-27

    1 trial site

  • Phase 1DW60142023-02-14

    1 trial site

  • Phase 1DW60142022-11-01

    1 trial site

  • Phase 1DW60132022-06-10

    1 trial site

  • Phase 1DW60132022-04-04

    1 trial site

Show 33 more
  • Phase 1DW60122021-07-13

    1 trial site

  • Phase 2DW2008S2020-11-23

    10 trial sites

  • Phase 2DW2008S2020-06-04
  • BioequivalenceDW5266(리바록사반20밀리그램)2020-03-17

    2 trial sites

  • Phase 1DW60082019-12-16

    2 trial sites

  • BioequivalenceDW5268(에제티미브/아토르바스타틴 10/40밀리그램)2019-09-06

    2 trial sites

  • BioequivalenceDW5266(리바록사반20밀리그램)2019-06-21

    2 trial sites

  • Phase 3자보란테정2018-11-07

    19 trial sites

  • Phase 1DW20052018-04-27

    1 trial site

  • Phase 1DW2008S2018-02-26

    2 trial sites

  • Phase 1DW60092018-01-10

    1 trial site

  • Phase 1DW60102017-04-10

    1 trial site

  • Phase 1DW60082017-02-07

    1 trial site

  • Phase 1다코젠주2016-11-29

    3 trial sites

  • Phase 2aDW2007정2016-06-07

    8 trial sites

  • Bioequivalence돈페질정23밀리그램2015-12-03

    2 trial sites

  • Bioequivalence동화바레니클린정1밀리그램(가칭)2015-11-25

    2 trial sites

  • Bioequivalence디에스오정40밀리그램(Esomeprazole magnesium dihydrate43.38mg (Esomeprazole로서 40mg))2015-06-30

    2 trial sites

  • Phase 1DW1029M건조엑스2014-09-24

    1 trial site

  • Bioequivalence스타넵틴정2014-09-19

    2 trial sites

  • Phase 1DW1029M건조엑스2014-08-25

    1 trial site

  • Phase 1DW1029M건조엑스2014-08-25

    1 trial site

  • Phase 1자보란테정2014-05-30

    1 trial site

  • Bioequivalence에탈로프정10밀리그램(에스시탈로프람옥살산염)2013-12-27

    2 trial sites

  • Phase 1DW1029M건조엑스2013-10-18

    1 trial site

  • Phase 2bDW1029M건조엑스2013-04-19

    10 trial sites

  • Bioequivalence메녹틸정(옥틸로늄브롬화물)(변경허가 후)2013-03-22

    2 trial sites

  • Bioequivalence동화세레콕시브캡슐200밀리그램2013-03-21

    2 trial sites

  • Bioequivalence동화로수바스타틴정10밀리그램2013-02-06

    2 trial sites

  • Bioequivalence동화아리피프라졸10밀리그램2012-07-27

    2 trial sites

  • Bioequivalence판토프라정40밀리그람2012-07-18

    2 trial sites

  • Phase 3자보란테정2012-07-16

    35 trial sites

  • Phase 1DWCZP정100밀리그램2012-06-11

    6 trial sites

Publications

PubMed · affiliation-matched
Show 9 more publications

Patents

KIPRIS · applicant-matched
Show 187 more patents

AI reads

MAA server logs · IP-verified
107
Times AI engines pulled DONGWHA PHARM.CO.,LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

105
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 0
Last 7 days
81
live 0
Last 30 days
107
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot95
  • GoogleGoogleOther4
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DONGWHA PHARM.CO.,LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products · R&D. Send us materials and we will add them

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DongKookPharmaceuticalCo.,Ltd.3 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

HANS BIOMED CORPORATION2 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

WonIk Co.,LTD2 shared

WonIk, founded in 1983 and KOSDAQ-listed in 1997, operates pressure sensor, dermo-cosmetic, and medical device distribution businesses.

Chabiotech Co.,Ltd.2 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

PharmaResearch Co., Ltd.2 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

Humedix Co., Ltd.2 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

Wonbiogen Co.,Ltd.2 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

BNC KOREA, Inc.2 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

Dong-A Socio Holdings Co.,Ltd2 shared

Founded 1949, KOSPI-listed 1970, Dong-A Socio Holdings makes Bacchus and pharma/non-pharma goods, allied with Meiji Seika on biosimilars.

Hanmi Science Co.,Ltd1 shared

KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.

BioPlus Co., Ltd1 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

GC Biopharma Corp.1 shared

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition